Salt form disclosure
Available: 0.25mg, 0.5mg, 1mg Metabolic Health Tirzepatide Dual GIP/GLP-1 receptor agonist representing the next generation of metabolic health therapeutics
Record each vial against the protocol so an outlier can be traced later
Common side effects include: Injection site reactions mild pain, redness, swelling, or bruising at the injection site, typically resolving within a few days Headache usually transient and manageable with standard analgesia Nausea or dizziness particularly in the initial treatment phase Skin reactions including itching, mild rash, or acneiform eruptions Temporary urine discolouration red or orange urine is harmless and expected Diarrhoea or flushing usually mild and self-limiting In patients with severe megaloblastic anaemia, low potassium levels (hypokalaemia) may occur during initial intensive treatment, but this is uncommon in routine maintenance therapy
They are not dosage forms, not for ingestion, and not for human or veterinary use
Our office is located on the second floor of the Wellstar Vinings Health Park at 4441 Atlanta Road SE, Suite 207, Smyrna, GA 30080